Table 2

Concentrations of immunomodulatory factors in CVL of 21 pregnant and 24 non-pregnant women from Los Angeles.

    Total

    Pregnant

    Non-pregnant

p-value

Factor

n detectable*

Median (IQR) or geometric mean [pg/ml]#

Median (IQR) or geometric mean [pg/ml]#

Median (IQR) or geometric mean [pg/ml]#


EGF

45

90.2 (75.1, 128.8)

89.0

102.6

0.33

Eotaxin

45

38.9 (28.5, 47.2)

36.1

40.7

0.43

FGF-2

34

11.1 (7.7, 21.5)

9.6 (< 3.2; 18.5)

8.9 (< 3.2; 17.8)

0.95

Flt-3 ligand

2

184.3 (14.9, 353.6)

< 4.6 (< 4.6; < 4.6)

< 4.6 (< 4.6; < 4.6)

0.97

Fractalkine

36

132.4(66.2, 293.6)

106.7(29.7; 171.7)

95.0 (11.2; 222.4)

0.92

G-CSF

45

383.4 (131.5, 741.6)

307.9

249.5

0.66

GM-CSF

36

77.8 (44.8, 137.3)

60.8 (18.8; 105.1)

64.6 (26.4; 123.5)

0.33

GRO

45

1,368.1 (756.0, 1,984.4)

1,175.8 (472.4; 2,328.0)

1,487.0 (1,109.0; 1,859.5)

0.49

IFNγ

42

2.0 (1.0, 3.8)

1.6

2.2

0.39

IFNα2

4

213.5 (93.1, 316.8)

< 40.6 (< 40.6; 40. < 6)

< 40.6 (< 40.6; < 40. 6)

0.98

IL-10

17

3.8 (1.1, 30.4)

< 0.5 (< 0.5; 1.3)

< 0.5 (< 0.5; 1.1)

0.90

IL-12p40

42

93.3 (58.2, 180.3)

105.7

86.2

0.48

IL-12p70

24

4.7 (2.5, 13.6)

0.9 (< 0.8; 3.5)

1.8 (< 0.8; 5.5)

0.49

IL-13

12

5.0 (1.9, 20.4)

< 0.9 (< 0.9; < 0.9)

< 0.9 (< 0.9; 1.7)

0.59

IL-15

18

4.0 (1.1, 5.6)

< 0.7 (< 0.7; 1.1)

< 0.7 (< 0.7; 4.0)

0.70

IL-17

45

3.0 (2.0, 4.2)

2.6

3.2

0.39

IL-1α

45

664.2 (278.9, 1,526.3)

812.8

502.5

0.15

IL-1β

28

30.4 (7.6, 49.8)

6.8 (< 0.7; 37.6)

6.9 (< 0.7; 40.5)

0.97

IL-1ra

45

> 10,000 (> 10,000, > 10,000)

> 10,000 (> 10,000, > 10,000)

> 10,000 (> 10,000, > 10,000)

0.37

IL-2

16

9.3 (1.6, 18.6)

< 0.6 (< 0.6; 6.6)

< 0.6 (< 0.6; 0.8)

0.15

IL-3

43

144.0 (69.8, 187.2)

155.5 (110.2; 187.2)

142.2 (58.5; 171.0)

0.65

IL-4

1

27.9

< 1.1 (< 1.1; < 1.1)

< 1.1 (< 1.1; < 1.1)

0.37

IL-5

12

0.1 (0.1, 0.3)

< 0.1 (< 0.1; < 0.1)

< 0.1 (< 0.1; 0.1)

0.51

IL-6

38

42.2 (22.1, 94.9)

34.1 (5.6; 91.7)

29.0 (9.1; 65.9)

1.00

IL-7

15

28.8 (7.6, 39.4)

< 4.0 (< 4.0; 17.1)

< 4.0 (< 4.0; 6.7)

0.74

IL-8

45

405.8 (254.3, 958.6)

526.0

429.4

0.52

IL-9

41

25.9 (6.8, 49.0)

11.6

18.4

0.28

IP-10

45

112.6 (40.5, 263.7)

97.7

144.2

0.29

MCP-1

44

79.3 (22.2, 208.6)

41.1

111.4

0.03

MCP-3

3

14.2 (6.0, 20.2)

< 3.7 (< 3.7; < 3.7)

< 3.7 (< 3.7; < 3.7)

0.62

CCL22

42

63.2 (25.9, 131.9)

29.7

89.7

0.001

MIP-1α

44

62.0 (36.6, 86.0)

54.3

57.5

0.79

MIP-1β

35

55.2 (30.9, 108.9)

35.3 (9.5; 69.9)

46.8 (22.0; 91.5)

0.52

sCD40L

8

52.0 (24.5, 98.8)

< 9.0 (< 9.0; < 9.0)

< 9.0 (< 9.0; < 9.0)

0.90

sIL-2Ra

6

22.9 (15.0, 27.5)

< 7.7 (< 7.7; < 7.7)

< 7.7 (< 7.7; < 7.7)

0.60

TGFα

38

14.4 (5.9, 24.0)

9.5 (2.8; 26.5)

12.9 (3.8; 17.3)

0.72

TNFα

43

0.8 (0.5, 2.8)

0.8 (0.5; 2.4)

0.9 (0.5; 2.5)

0.84

TNFβ

13

7.1 (5.0, 13.6)

< 3.4 (< 3.4; 4.3)

< 3.4 (< 3.4; 4.7)

1.00

VEGF

43

56.2 (37.1, 102.6)

53.3

73.9

0.29


IQR = interquartile range

* number of samples with concentrations above the detection limit of the kit plus 2 standard deviations as provided by the manufacturer;

# undetectable samples were imputed with a values just below the cut off, geometric means (a single number) are shown for variables normally distributed on the log scale, median and interquartile range are shown for non-normally distributed variables

Walter et al. BMC Infectious Diseases 2011 11:263   doi:10.1186/1471-2334-11-263

Open Data